Chemotherapy-induced peripheral neuropathy (CIPN) is a common and often persistent adverse effect of oxaliplatin- and paclitaxel-based chemotherapy. While exercise is frequently recommended for patients with CIPN, it remains unclear whether exercise mitigates neuropathic injury itself or primarily improves physical function and quality of life.
This randomized controlled trial evaluates the effects of exercise on CIPN during and after chemotherapy. Patients receiving oxaliplatin for colorectal cancer or paclitaxel for gynecologic cancer are randomized to an exercise intervention or usual-care control. Neuropathy severity is assessed using objective neurophysiological measures, blood biomarkers, and validated clinical and patient-reported outcomes.
Diagnosis of colorectal cancer (oxaliplatin cohort) or gynecologic cancer (paclitaxel cohort)
Planned initiation of oxaliplatin- or paclitaxel-based chemotherapy
Karnofsky Performance Status ≥70
Ability to provide written informed consent
Pre-existing peripheral neuropathy from other causes
Severe comorbidities limiting safe participation in exercise
Regular participation in a structured moderate- to high-intensity exercise program comparable to the study intervention prior to enrollment.
Cognitive impairment interfering with study participation